Lurbinectedin . Según Jason Niu , Oncólogo Torácico y Director del Programa de Cáncer de Pulmón en el Centro de Cáncer Banner MD Anderson , Espero que este Agente Sea Aprobado Pronto.

JESSICA HERGERT
Monday, March 16, 2020

Jiaxin ( Jason ) MD, PhD

In an interview with Oncology Nursing News' sister publication, OncLive, Jason Niu, a thoracic oncologist and director of the Lung Cancer Program at the Banner MD Anderson Cancer Center, discussed the evolution in the treatment paradigm for patients with ES-SCLC.

In the second-line setting, what developments have been made with Lurbinectedin?

Lurbinectedin is a very interesting compound. The first-generation agent trabectedin (Yondelis) is approved to treat patients with sarcoma, but lurbinectedin is more of a second-generation synthetic drug. As a result, lurbinectedin is a more potent and better-tolerated agent than trabectedin.

A phase I/Ib study looked at lurbinectedin alone and in combination with doxorubicin, and results showed a synergistic effect between the combined agents. As a result, a phase II basket trial enrolling patients with ovarian cancer, breast cancer, and SCLC was conducted. The results of the SCLC cohort were presented at the 2019 ASCO Annual Meeting.

The trial enrolled about 105 patients with platinum-sensitive and platinum-resistant SCLC. Both groups showed impressive responses. In particular, single-agent lurbinectedin demonstrated up to a 45% response rate and an 11-month median OS for patients with platinum-sensitive SCLC.

This agent is well tolerated. We mainly see hematologic toxicities, which are manageable from a medical oncology standpoint. As such, I fully expect this agent to be approved soon.

...